Eli Lilly and Company $LLY Shares Purchased by Advantage Trust Co

Advantage Trust Co increased its stake in shares of Eli Lilly and Company (NYSE:LLY) by 27.0% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 876 shares of the company’s stock after purchasing an additional 186 shares during the quarter. Eli Lilly and Company accounts for 0.3% of Advantage Trust Co’s holdings, making the stock its 25th largest holding. Advantage Trust Co’s holdings in Eli Lilly and Company were worth $683,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. DecisionMap Wealth Management LLC grew its stake in Eli Lilly and Company by 111.4% during the 2nd quarter. DecisionMap Wealth Management LLC now owns 1,264 shares of the company’s stock worth $985,000 after purchasing an additional 666 shares in the last quarter. Divergent Planning LLC purchased a new stake in Eli Lilly and Company during the 2nd quarter worth about $1,548,000. Syntegra Private Wealth Group LLC lifted its holdings in Eli Lilly and Company by 27.0% during the 2nd quarter. Syntegra Private Wealth Group LLC now owns 1,311 shares of the company’s stock worth $1,022,000 after buying an additional 279 shares during the last quarter. Liberty One Investment Management LLC lifted its holdings in Eli Lilly and Company by 4.7% during the 2nd quarter. Liberty One Investment Management LLC now owns 37,454 shares of the company’s stock worth $29,196,000 after buying an additional 1,685 shares during the last quarter. Finally, Klingman & Associates LLC lifted its holdings in Eli Lilly and Company by 18.3% during the 2nd quarter. Klingman & Associates LLC now owns 2,232 shares of the company’s stock worth $1,740,000 after buying an additional 346 shares during the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.

Eli Lilly and Company Stock Up 0.8%

Eli Lilly and Company stock opened at $808.88 on Tuesday. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $935.63. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. The company has a market capitalization of $765.57 billion, a P/E ratio of 52.87, a PEG ratio of 1.15 and a beta of 0.47. The stock has a 50-day simple moving average of $756.56 and a 200-day simple moving average of $766.20.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, beating the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The business had revenue of $15.56 billion during the quarter, compared to the consensus estimate of $14.40 billion. During the same period in the previous year, the business earned $3.92 EPS. The business’s quarterly revenue was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Equities research analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on the company. The Goldman Sachs Group lifted their price target on Eli Lilly and Company from $876.00 to $879.00 and gave the stock a “buy” rating in a report on Friday, October 10th. Cantor Fitzgerald set a $925.00 price target on Eli Lilly and Company and gave the stock an “overweight” rating in a report on Thursday, October 9th. Wall Street Zen downgraded Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a report on Saturday, September 20th. Daiwa America downgraded Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a report on Sunday, August 17th. Finally, Morgan Stanley decreased their price target on Eli Lilly and Company from $1,028.00 to $1,023.00 and set an “overweight” rating for the company in a report on Friday, October 3rd. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $938.61.

Insider Activity

In related news, CEO David A. Ricks acquired 1,632 shares of Eli Lilly and Company stock in a transaction on Tuesday, August 12th. The stock was purchased at an average cost of $644.77 per share, with a total value of $1,052,264.64. Following the purchase, the chief executive officer directly owned 546,601 shares in the company, valued at approximately $352,431,926.77. The trade was a 0.30% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Daniel Skovronsky acquired 1,000 shares of Eli Lilly and Company stock in a transaction on Tuesday, August 12th. The shares were bought at an average cost of $634.40 per share, with a total value of $634,400.00. Following the completion of the purchase, the executive vice president owned 137,660 shares in the company, valued at $87,331,504. The trade was a 0.73% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders bought 4,514 shares of company stock worth $2,894,841 over the last quarter. 0.13% of the stock is owned by insiders.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.